Real life data from Turkey regarding the impact of first-line sunitinib and pazopanib in metastatic renal cell cancer.

Abstract

e16075 Background: Although the distribution in the world varies widely, renal cell carcinoma (RCC) is the ninth most common cancer, especially in males. It’s the seventh most common cancer in Turkey. In this study, the progression-free survival (PFS) and overall survival (OS) of patients with metastatic RCC (mRCC) who were treated at 13 centers in our country were evaluated and the efficacy of first-line treatment approaches was compared. Methods: Data of mRCC patients admitted to 13 outpatient clinics in Turkey between 2008 and 2018 were reviewed retrospectively. Demographic characteristics, pre-treatment clinical evaluations, information about treatment approaches and survival outcomes of the patients were collected. All medical records were collected by a detailed review of the patients’ charts. The median and percentage values were frequently signified for defining of central trends. Kaplan-Meier method was applied for OS analyzes and log-rank test with Cox-regression models were applied for the evaluation of prognostic factors. Results: Data from files of 262 patients were reviewed. Twelve of these patients were excluded from the study because they could not receive treatment due to comorbidities and other reasons at metastatic stage of the disease. Of the patients, 100 (40%) were female and 150 (60%) were male. Median age was 60 (range 21-83). For the entire group, the median PFS (mPFS) was 27.6 months and the median overall survival (mOS) was 46.1 months. In terms of first-line treatment of metastatic disease, 41.3% of the patients received sunitinib, 48.8% of the patients received pazopanib, 15.8% of the patients received other treatments. PFS of the patients receiving sunitinib, pazopanib and the other treatments were 26.3 months, 34.2 months and 14.2 months, respectively. There was no statistically significant difference between PFS of the patients receiving sunitinib and pazopanib (p = 0.05). mOS was 54 months in sunitinib arm, 54.9 months in pazopanib arm and 23.3 months in the other treatment arm. There was no statistically significant difference between two treatment agents in terms of mOS (p = 0.43). Conclusions: Pazopanib was more commonly prescribed in Turkey. There were no statistically significant differences between mPFS and mOS of the patients who received sunitinib and pazopanib for the first-line treatment of mRCC. With increased use of immunotherapeutic agents for the first-line treatment of mRCC in our country, improvement in mOS could be expected.

Evaluation of the effectiveness and tolerability of sunitinib and pazopanib in the first line treatment of metastatic renal cell carcinoma

“…A median PFS of 24.3 months was observed in the sunitinib arm, while a median PFS of 34.2 months was observed in the pazopanib arm. There was no statistically significant difference between the two drugs in terms of PFS [14].…”

“…On the other hand, OS data from another study that compared pazopanib and sunitinib in the first-line treatment of mRCC showed pazopanib to be non-inferior to sunitinib, with median OS times for pazopanib and sunitinib reported as 26.9 months (95% CI, 23.1-35.6) and 26.1 months (95% CI, 20.7-31.6), respectively [13]. Considering the real-life data, in the study of Isik U. et al [14], sunitinib and pazopanib data were evaluated in first-line treatment in meta- static clear cell renal cell carcinoma. A median PFS of 24.3 months was observed in the sunitinib arm, while a median PFS of 34.2 months was observed in the pazopanib arm.…”

Coexistence of Cd44 and Ki-67 as the Prognostic Markers in Renal Cell Carcinoma

“…The incidence of RCC is increasing worldwide, with rates varying by age, race, sex and country (2). Also, it is the seventh most common cancer in Turkey (3).…”